Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00555347 · ClinicalTrials.gov registry record · Phase 2
Use of Armodafinil for Fatigue in Sarcoidosis
A Phase 2 study, sponsored by University of Cincinnati.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT00555347: Completed Phase 2 study, sponsored by University of Cincinnati.
NCT00555347 is a Phase 2 study that has completed, run by University of Cincinnati. The registered enrollment target is 20 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00555347, a Phase 2 study, has completed, sponsored by University of Cincinnati.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
To determine the effect of Armodafinil (Nuvigil) on fatigue and sleep in sarcoidosis.
Interventions
- DRUG Placebo
- DRUG Armodafinil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2007-10 |
| Est. Completion | 2011-08 |
| Phase | Phase 2 |
What the finished NCT00555347 record still lists
NCT00555347 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00555347 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00555347 about?
NCT00555347 is a clinical study titled "Use of Armodafinil for Fatigue in Sarcoidosis". To determine the effect of Armodafinil (Nuvigil) on fatigue and sleep in sarcoidosis.
What is the current status of trial NCT00555347?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2007-10. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00555347?
The interventions under investigation include: Placebo (DRUG), Armodafinil (DRUG).
Who is sponsoring clinical trial NCT00555347?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00555347's enrollment target sits among peer trials
20 1805th of 2000 higher than 107 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia